These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 14686701

  • 1. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K.
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
    [Abstract] [Full Text] [Related]

  • 2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
    Clin Cancer Res; 2005 Feb 01; 11(3):1287-93. PubMed ID: 15709200
    [Abstract] [Full Text] [Related]

  • 3. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
    Urology; 2010 Apr 01; 75(4):805-12. PubMed ID: 20156648
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello M, D'Alessandro N.
    Int J Oncol; 2006 Apr 01; 28(4):923-30. PubMed ID: 16525642
    [Abstract] [Full Text] [Related]

  • 5. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
    Int J Oncol; 2006 Sep 01; 29(3):713-9. PubMed ID: 16865289
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M.
    Mol Pharmacol; 2009 Aug 01; 76(2):290-300. PubMed ID: 19461054
    [Abstract] [Full Text] [Related]

  • 7. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
    Horie R, Watanabe T, Umezawa K.
    Drug News Perspect; 2006 May 01; 19(4):201-9. PubMed ID: 16823495
    [Abstract] [Full Text] [Related]

  • 8. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S.
    Clin Cancer Res; 2004 Oct 15; 10(20):6821-9. PubMed ID: 15501958
    [Abstract] [Full Text] [Related]

  • 9. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 10. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K, Morioka H, Nishimoto K, Suzuki Y, Susa M, Nakayama R, Kawai A, Sonobe H, Takaishi H, Ozaki T, Yabe H, Umezawa K, Toyama Y.
    Cancer Lett; 2008 Dec 18; 272(2):336-44. PubMed ID: 18760530
    [Abstract] [Full Text] [Related]

  • 11. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, Kuratomi Y, Yamamoto T, Weinstein IB, Komune S.
    Head Neck; 2006 Feb 18; 28(2):158-65. PubMed ID: 16355386
    [Abstract] [Full Text] [Related]

  • 12. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N, Miyakawa Y, Kohmura K, Umezawa K, Ikeda Y, Kizaki M.
    Leuk Res; 2007 Nov 18; 31(11):1529-35. PubMed ID: 17466373
    [Abstract] [Full Text] [Related]

  • 13. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.
    Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M.
    Cancer Res; 2003 Jan 01; 63(1):107-10. PubMed ID: 12517785
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E, Umezawa K.
    Biomed Pharmacother; 2006 Nov 01; 60(9):578-86. PubMed ID: 16978829
    [Abstract] [Full Text] [Related]

  • 16. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A, Umezawa K, Bonavida B.
    Drug Resist Updat; 2007 Nov 01; 10(1-2):1-12. PubMed ID: 17306602
    [Abstract] [Full Text] [Related]

  • 17. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
    Arthritis Res Ther; 2005 Nov 01; 7(6):R1348-59. PubMed ID: 16277688
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
    Lampiasi N, Azzolina A, Umezawa K, Montalto G, McCubrey JA, Cervello M.
    Cancer Lett; 2012 Sep 01; 322(1):35-44. PubMed ID: 22343223
    [Abstract] [Full Text] [Related]

  • 20. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
    Makino S, Mitsutake N, Nakashima M, Saenko VA, Ohtsuru A, Umezawa K, Tanaka K, Hirano A, Yamashita S.
    J Dermatol Sci; 2008 Sep 01; 51(3):171-80. PubMed ID: 18406579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.